ANI results, reiterates guidance

 

• Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82
• Delivered record adjusted non-GAAP EBITDA of $37.6 million, and adjusted non-GAAP diluted earnings per share of $1.21
• Rare Disease business delivered Q1 net revenues of $36.9 million, representing year-over-year growth of 126.2%
• Reiterated 2024 guidance of net revenues of $520 million to $542 million, adjusted non-GAAP EBITDA of $135 million to $145 million and adjusted non-GAAP earnings per share of $4.26 to $4.67
• Guidance includes Purified Cortrophin^® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin Gel) net revenues of $170 million to $180 million, representing year-over-year growth of 52% to 61%

https://www.biospace.com/article/releases/ani-pharmaceuticals-reports-record-first-quarter-2024-financial-results-and-reiterates-2024-guidance/